Your browser doesn't support javascript.
loading
[Expression of ProEXC and PRMT5 in cervical adenocarcinoma and their clinical significance].
Cui, H X; Lou, X L; Xia, W; Zhang, Y S; Cheng, X Y; Deng, L F.
Afiliación
  • Cui HX; Department of Pathology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
  • Lou XL; Department of Pathology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
  • Xia W; Department of Pathology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
  • Zhang YS; Department of Pathology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
  • Cheng XY; Department of Pathology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
  • Deng LF; Department of Gynecologic, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Zhonghua Yi Xue Za Zhi ; 103(48): 3967-3971, 2023 Dec 26.
Article en Zh | MEDLINE | ID: mdl-38129175
ABSTRACT
This study observed the expression of ProEXC protein and PRMT5 protein in cervical adenocarcinoma and adjacent tissues, exploring the relationship between the expression of ProEXC and PRMT5 and the auxiliary diagnosis of cervical adenocarcinoma, as well as the clinical pathological parameters. A total of 88 specimens diagnosed with cervical adenocarcinoma from the Second Affiliated Hospital of Soochow University between 2015 and 2020 were collected. Immunohistochemistry was employed to detect the expression of ProEXC and PRMT5 in cervical adenocarcinoma and adjacent tissues, and statistical analysis was conducted. The Cancer Genome Atlas (TCGA) database was utilized to analyze the correlation between the prognosis of cervical adenocarcinoma patients and the expression of ProEXC and PRMT5, as well as their related gene pathways. The GSE39293 dataset from the Gene Expression Omnibus (GEO) was selected to compare the expression levels of ProEXC and PRMT5 in cervical adenocarcinoma cell lines (HELA) before and after antiviral drug treatment.In cervical adenocarcinoma tissues, the expression of ProEXC protein (95.5% vs 4.6%, P<0.001) and PRMT5 protein (81.8% vs 26.1%, P<0.001) was significantly higher than in surrounding adjacent tissues. Their expression was correlated with the tumor's T stage, lymph node metastasis, and human papillomavirus (HPV) infection (P<0.05). TCGA database analysis showed that patients with high expression of MCM2 in PRMT5 and ProEXC had a lower overall survival rate (P<0.05), while the expression of TOP2A was not significantly correlated with survival. In the GSE39293 dataset, the expression of MCM2 (9.34 vs 9.68, P<0.001) and PRMT5 (8.16 vs 8.26, P=0.087) in cells decreased after treatment with cidofovir, while TOP2A (8.54 vs 8.42, P=0.056) expression did not change significantly. In the drug-resistant group, the expression of PRMT5 (8.42 vs 8.16, P=0.002) and MCM2 (9.51 vs 9.34, P=0.029) increased, while TOP2A (8.06 vs 8.54, P<0.001) expression decreased. Gene set enrichment analysis (GSEA) suggested that high expression of ProEXC mainly affected the cell cycle pathway, while high expression of PRMT5 mainly affected the RNA splicing pathway.This study found that ProEXC protein and PRMT5 protein were highly expressed in cervical adenocarcinoma tissues, and the high-expression group had a poorer prognosis, showing a certain correlation with the clinical and pathological characteristics of cervical adenocarcinoma. This may be related to their influence on the cell cycle and RNA synthesis pathways, suggesting their potential significant roles in the progression of cervical adenocarcinoma.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Adenocarcinoma / Neoplasias del Cuello Uterino Límite: Female / Humans Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Asunto principal: Adenocarcinoma / Neoplasias del Cuello Uterino Límite: Female / Humans Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Año: 2023 Tipo del documento: Article País de afiliación: China